November 16, 2023
- CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
- The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
- This review assesses upadacitinib (Rinvoq) 15 mg, 30 mg, and 45 mg extended-released tablets, oral administration.
- Indication: For the treatment of adult patients with moderately to severely active ulcerative colitis whose condition has not responded to treatment, i.e., have had an inadequate response, loss of response, or intolerance to at least 1 of the conventional and/or biologic therapies.